Introduction Approximately 25% of patients with non–small cell lung cancer (NSCLC) present with unresectable stage III disease (IIIA to IIIC), for which standard concurrent chemoradiation therapy (cCRT) yields modest survival outcomes (1). Consolidation therapy with durvalumab after cCRT offers additional benefit, yet a considerable portion of pati
66 Reached
Black Lesion in Old Female
1972 Reached5 Comments11 Likes
Case of Increased Risk of Pregnancy-associated Breast Cancer Recurrence
1007 Reached2 Comments
Treatment of Recurrent Adult Medulloblastoma
2602 Reached1 Comments4 Likes
Management of Metastatic Prostate Cancer
1037 Reached5 Comments2 Likes
Pancytopenia, a rare presentation of hyperthyroidism
830 Reached2 Comments